21st.BIO
Investment Details
Investor Type
Venture Capital
Asset Class Focus
Venture Capital
Stage Focus
Seed, Early Stage, Series A, Series B, Growth, Late Stage, Pre-IPO, Buyout, Turnaround, Distressed
Geographical Focus
United States, United Kingdom, Germany, France, Italy, Denmark, Switzerland, Spain, Austria, Netherlands, Hungary, Sweden, Belgium, Norway, Finland, Poland, Czech Republic, Slovakia, Romania, Bulgaria
Industries Focus
- Healthcare
- Consumer Goods
- Materials
- Automotive
- Renewable Energy
- Agriculture
- Aerospace
- Pharmaceuticals
- Medical Devices
- Biotechnology
- Chemicals
- Environmental Services
- Food
- Textiles
- Cosmetics
Investor Details Founded: 2020
21st.BIO is a Danish venture capital firm specializing in early-stage investments in the biotechnology sector. The firm focuses on supporting companies that develop sustainable bio-based alternatives across various industries, including food, materials, and agriculture. By leveraging advanced biotechnological processes, 21st.BIO aims to facilitate the transition towards more sustainable production methods.
The firm's investment strategy centers on identifying and nurturing innovative biotech startups that align with its mission of promoting sustainability. 21st.BIO provides not only financial backing but also technical expertise to help portfolio companies optimize their production processes. This support is crucial for scaling up operations and achieving commercial viability in the competitive biotech industry.
Since its inception, 21st.BIO has demonstrated a commitment to fostering growth in the biotech sector by investing in companies that offer promising solutions to global challenges. The firm's approach combines strategic investment with a focus on sustainability, positioning it as a key player in advancing the biotech industry's contribution to a more sustainable future.
Requirements
- Companies specializing in precision fermentation technology
- Start-ups and established manufacturers in the biotech sector
- Innovations in sustainable protein production
- Projects with potential for large-scale industrial application
- Collaborations aiming to bridge the gap between lab success and market-ready products
Contact
[Official Website Hidden]
[HQ Location Hidden]
[Contact Number Hidden]
Portfolio Companies
- Reshape Biotech
- AMSilk
Mentioned In
-
$19.95
-
$19.95
-
$19.95
-
$14.95
-
$24.95
-
$24.95
-
$24.95
-
$19.95
-
$19.95
-
$99.00
-
$24.95
-
$24.95
-
$19.95
-
$49.95
-
$19.95
Claim this Investor
Are you an official representative of 21st.BIO?
Claim this investor to update information, manage your profile, and get a verified seal.
Claim